Compare EIC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | NKTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 108 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 198.2M |
| IPO Year | N/A | 2020 |
| Metric | EIC | NKTX |
|---|---|---|
| Price | $10.54 | $2.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $12.63 | $11.33 |
| AVG Volume (30 Days) | 97.0K | ★ 543.9K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.17 | $1.63 |
| 52 Week High | $13.92 | $3.65 |
| Indicator | EIC | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 38.27 |
| Support Level | $10.37 | $1.96 |
| Resistance Level | $11.34 | $2.78 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 32.61 | 2.87 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.